

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities, nor is it an invitation or offer to or a solicitation of any offer to acquire, purchase or subscribe for any securities in any jurisdiction in which such invitation, offer, solicitation or sale would be unlawful absent the filing of a registration statement or the availability of an applicable exemption from registration or other waiver.*

*This announcement is not for release, publication or distribution, in whole or in part, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.*

*Reference is made to the listing document dated June 30, 2025 (the “**Listing Document**”) issued by Sunshine Lake Pharma Co., Ltd. (the “**Company**”). Unless the context requires otherwise, the capitalised terms used in this announcement shall have the same meanings as defined in the Listing Document.*



**SUNSHINE LAKE PHARMA CO., LTD.**

**廣東東陽光藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**Stock code: 6887**

**LISTING BY WAY OF INTRODUCTION  
OF 112,712,832 H SHARES OF RMB1.00 EACH  
ON THE MAIN BOARD OF  
THE STOCK EXCHANGE OF  
HONG KONG LIMITED**

*Sole Sponsor*



The Company has applied to the Stock Exchange for the listing of, and permission to deal in, 112,712,832 H Shares on the Stock Exchange. Such number of H shares to be issued is based on the assumption that all HEC CJ Pharm H Shares held by the Share Exchange Shareholders are exchanged into the H Shares according to the Share Exchange Ratio and the terms of the Merger Agreement, and no shares are issued pursuant to the Introduction. Please refer to “Share Capital” and “History, Development and Corporate Structure” of the Listing Document for more details. The Listing of the H Shares on the Main Board of the Stock Exchange is by way of introduction and there are no H Shares being issued in connection with the Listing, other than to the Share Exchange Shareholders. Dealings in the H Shares on the Stock Exchange are expected to commence at 9:00 a.m. on Thursday, August 7, 2025, subject to the fulfilment or waiver (as applicable) of the Conditions and the completion of the Privatization. The H Shares will be traded in board lots of 100 H Shares each. The stock code of the H Shares is 6887.

The Company has made the Privatization Proposal to privatize HEC CJ Pharm by way of merger by absorption by issuing H Shares as consideration to acquire the Share Exchange HEC CJ Pharm H Shares held by the Share Exchange Shareholders in accordance with the PRC Company Law, other applicable PRC laws, Hong Kong laws, the Takeovers Code and the Listing Rules. For every Share Exchange HEC CJ Pharm H Share cancelled under the Privatization Proposal, an exchange ratio of 0.263614 new H Shares will be adopted and a corresponding number of H Shares will be issued. In addition, as an integral part of the Privatization Proposal, subject to the fulfilment (or waiver, as applicable) of all the Pre-Conditions and the Conditions, HEC CJ Pharm will pay a Special Dividend to HEC CJ Pharm Shareholders whose names appear on the register of members of HEC CJ Pharm on the Special Dividend Record Date other than the Company and its subsidiaries (if applicable). The Special Dividend payable is based on HK\$1.50 per HEC CJ Pharm Share for a total number of 427,567,700 HEC CJ Pharm Shares held by the aforementioned shareholders. Upon the fulfilment of the Conditions to the implementation and following completion of the Privatization Proposal, (a) HEC CJ Pharm will be delisted from the Stock Exchange; (b) the Company's H Shares will be listed on the Stock Exchange; (c) the Share Exchange Shareholders will become Shareholders; and (d) our Company will assume all assets, liabilities, interests, businesses, employees, contracts and all other rights and obligations of HEC CJ Pharm and HEC CJ Pharm will be eventually deregistered in the PRC. All domestic shares of HEC CJ Pharm held by our Company (representing all domestic shares of HEC CJ Pharm in issue) and all HEC CJ Pharm H Shares held by our Company and through its subsidiary will be cancelled after completion of the Merger. Please refer to "History, Development and Corporate Structure – Structure of the Introduction and the Privatization" of the Listing Document for more details.

Subject to the granting of the approval of listing of, and permission to deal in, the H Shares on the Main Board of the Stock Exchange as well as compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the commencement date of dealings in the H Shares on the Stock Exchange or such other date as determined by HKSCC.

Settlement of transactions between Exchange Participants (as defined in the Listing Rules) is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of HKSCC and HKSCC Operational Procedures in effect from time to time. Potential investors should seek the advice of their stockbroker or other professional advisers for the details of the settlement arrangements as such arrangements may affect their rights and interests.

Copies of the Listing Document which are issued in accordance with the requirements under the Listing Rules will be available for information purposes during normal business hours for a period of 14 days from the date of the Listing Document at the office of the Sole Sponsor located at the following address:

China International Capital Corporation Hong Kong Securities Limited, 29/F, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong.

The Listing Document is also available on the Stock Exchange's website at [www.hkexnews.hk](http://www.hkexnews.hk) and on the Company's website at [www.hecpharm.com](http://www.hecpharm.com) from June 30, 2025.

**There is no assurance that the Introduction, the Privatization and the Listing will take place, or as to when it may take place. Further announcement(s) will be made by the Company in relation to the Introduction, the Privatization and the Listing as and when appropriate.**

By order of the board of  
**Sunshine Lake Pharma Co., Ltd.**  
**Zhang Yingjun**  
*Chairman*

Hong Kong, June 30, 2025

*As at the date of this announcement, the directors of the Company are Dr. ZHANG Yingjun and Dr. LI Wenjia as executive Directors; Mr. ZHANG Yushuai, Mr. TANG Xinfu, Mr. ZHU Yingwei, Mr. ZENG Xuebo, Ms. DONG Xiaowei and Ms. WANG Lei as non-executive Directors; and Dr. LI Xintian, Dr. MA Dawei, Dr. YIN Hang Hubert, Dr. LIN Aiwei and Dr. YE Tao as independent non-executive Directors.*